

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * <u>Duatschek Stephanie</u> (Last) (First) (Middle) <u>300 PROFESSIONAL DRIVE</u> (Street) <u>GAITHERSBURG MD 20879</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>08/05/2026</u>	3. Issuer Name and Ticker or Trading Symbol <u>Emergent BioSolutions Inc. [EBS]</u> Foreign Trading Symbol 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director10% Owner ☒ Officer (give title below)Other (specify below) EVP, CGO	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) ☒ Form filed by One Reporting Person Form filed by More than One Reporting Person
---	--	---	--

Table I - Non-Derivative Securities Beneficially Owned			
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	197,416 ⁽¹⁾	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)							
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Employee Stock Option (Right to buy)	(2)	07/08/2028	Common Stock	6,772	59.07	D	
Employee Stock Option (Right to buy) (Common Stock)	(3)	02/28/2029	Common Stock	7,250	41.38	D	
Employee Stock Option (Right to buy) (Common Stock)	(4)	03/05/2030	Common Stock	2,308	11.66	D	
Employee Stock Option (Right to buy) (Common Stock)	(5)	06/08/2030	Common Stock	9,231	8.39	D	
Employee Stock Option (Right to buy) (Common Stock)	(6)	03/12/2031	Common Stock	125,000	2.33	D	
Employee Stock Option (Right to buy) (Common Stock)	(7)	03/05/2032	Common Stock	62,500	5.8	D	
Employee Stock Option (Right to buy) (Common Stock)	(8)	03/02/2033	Common Stock	44,834	8.99	D	

Explanation of Responses:

1. Consists of 55,639 shares of common stock and 141,777 unvested RSUs from the Emergent Stock Incentive Plan. Each RSU represents a right to receive one share of common stock. The RSUs vest in three equal installments annually on the day prior to the anniversary date of the grant.

2. Granted on July 9, 2021 and as of the date of this filing all of the shares underlying the option are vested and exercisable.

3. Granted on March 1, 2022 and as of the date of this filing all of the shares underlying the option are vested and exercisable.

4. Granted on March 6, 2023 and as of the date of this filing all of the shares underlying the option are vested and exercisable.

5. Granted on June 9, 2023 and as of the date of this filing all of the shares underlying the option are vested and exercisable.

6. Granted on March 13, 2024 and vests in three installments beginning on the day prior to the anniversary date of the grant. As of the date of this filing, 83,250 of the shares underlying the option are vested and exercisable.

7. Granted on March 6, 2025 and vests in three installments beginning on the day prior to the anniversary date of the grant. As of the date of this filing, 20,813 of the shares underlying the option are vested and exercisable.

8. Granted on March 3, 2026 and vests in three installments beginning on the day prior to the anniversary date of the grant.

Remarks:

Exhibit list: Ex 24.1 - Power of Attorney

/s/ Richard S. Lindahl, Attorney-in-fact 08/12/2026

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

**LIMITED POWER OF ATTORNEY
FOR SECTION 16 REPORTING AND FORM 144 OBLIGATIONS**

Know all by these presents, that the undersigned hereby makes, constitutes and appoints with full power of substitution, the Chief Executive Officer (currently, Joseph Papa), the Chief Financial Officer (currently, Richard Lindahl), the Senior Vice President, General Counsel and Secretary (currently, Jessica Perl) of Emergent BioSolutions Inc. (the "Company"), and their respective successors, signing singly and each acting individually, with full power of substitution, as the undersigned's true and lawful attorney-in-fact with full power and authority as hereinafter described to:

(1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other forms and authentication documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder (the "Exchange Act") or any rule or regulation of the SEC;

(2) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of the Company, Forms 3, 4, and 5 (including any amendments thereto) in accordance with Section 16(a) of the Exchange Act;

(3) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to prepare, complete and execute any such Form 3, 4, or 5, prepare, complete and execute any amendment or amendments thereto, and any other forms and authentication documents and timely deliver and file such form or document with the SEC and any stock exchange or similar authority;

(4) any Notice of Proposed Sale of Securities on Form 144 to be filed with the SEC;

(5) seek or obtain, as the undersigned's representative and on the undersigned's behalf, information regarding transactions in the Company's securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to such attorney-in-fact and approves and ratifies any such release of information; and

(6) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the forms and documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming nor relieving, nor is the Company assuming nor relieving, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act. The undersigned acknowledges that neither the Company nor the foregoing attorneys-in-fact assume (i) any liability for the undersigned's responsibility to comply with the requirement of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act.

[Signature Page to Follow]

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 5 day of August 2026.

By: [Signature]
Name: STEPHANIE DVATSCHEK


STATE of MASSACHUSETTS

COUNTY OF SUFFOLK, to wit:

On this 5th day of August, 2026, before me, the undersigned personally appeared Stephanie Dvatshek (name of person(s) who make acknowledgement), known to me (or satisfactorily proven) to be the person(s) whose name(s) is/are subscribed to within the instrument and acknowledged that he/she/they executed the same for the purpose therein contained.

In witness hereof I hereunto set my hand and official seal.

(Notary Seal)



[Signature]
Signature of Notary Public
Notary Public
My Commission expires: 01/07/2033

